ReviewFrontiers in oncology2022
Atypical Rearrangements in APL-Like Acute Myeloid Leukemias: Molecular Characterization and Prognosis.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Tumor suppressor-like mutations mark a dosage-constrained dependency in leukemia.bioRxiv : the preprint server for biology · 2026Article
- Article
- Acute promyelocytic leukemia with a unique genetic signature: a case report and management.Discover oncology · 2026Article
- PML::RARA-negative APL-mimicking AML with a novel KMT2C::CREB3L2 fusion and RARA/RXRA-mediated sensitivity to all-trans retinoic acid.Annals of hematology · 2026Article
- Case report:Frontiers in oncology · 2026Article
- Uncovering theGenes · 2025Review
- A Rare t(3;15;17) in a Patient with Acute Promyelocytic Leukemia: Case Report and Review of the Literature.Diagnostics (Basel, Switzerland) · 2025Article
- CPSF6-RARγ interacts with histone deacetylase 3 to promote myeloid transformation in RARG-fusion acute myeloid leukemia.Nature communications · 2025Article
- Exploration of neuroprotective strategies in patients with acute promyelocytic leukemia complicated by cerebral hemorrhage.Frontiers in medicine · 2025Review
- Identification of novel NUP98::RARA fusion transcripts in acute promyelocytic leukemia with i(17)(q10) abnormality.American journal of cancer research · 2025Article
- Venetoclax combined with ATRA shows promising therapeutic potential for TFG:: RARA variant APL: a case report.Frontiers in oncology · 2025Article
- Review
- Risk factors and remaining challenges in the treatment of acute promyelocytic leukemia.International journal of hematology · 2024Review
- [APL-like leukemia with chromosomal translocation t(16;17): a case report and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Review
- Three-Way Translocation t(12;15;17) (p13;q24;q21) Found in Acute Promyelocytic Leukemia with Basophilic Differentiation.Hematology reports · 2024Article
- Therapy-Related Myeloid Neoplasm: Biology and Mechanistic Aspects of Malignant Progression.Biomedicines · 2024Review
- Case report: One case of acute myeloid leukemia M3 with atypical morphology.Frontiers in oncology · 2024Article
- Thrombosis in Myeloid Malignancies: From CHIP to AML.Cardiovascular & hematological disorders drug targets · 2024Review
- Charting a course through the acute promyelocytic leukemia (APL)-like nebula: the enigmatic cousins of APL.Haematologica · 2023Article
- Immunotherapy in Acute Myeloid Leukemia: A Literature Review of Emerging Strategies.Bioengineering (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute promyelocytic leukemia (APL) accounts for 10-15% of newly diagnosed acute myeloid leukemias (AML) and is typically caused by the fusion of promyelocytic leukemia with retinoic acid receptor α (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.